IS THE HIMS RALLY TAKING A NAP? π΄π
Evercore just slapped a new rating on Hims & Hers (HIMS), and itβs creating a lot of buzz. Here is the reality check you need before you press the "buy" button. π
The "Explain Like I'm 5" Breakdown:
* The Verdict: A top analyst just rated the stock as "In Line" (which is Wall Street talk for "Hold" or "It's fairly priced right now"). They set a target of $33.
* The "Home Renovation" Analogy: Imagine you buy a house, but you have to spend the next year fixing the roof and kitchen. It costs money now to make it worth more later.
* The Warning: The company is entering a "spending phase" through 2026. This means profits (EBITDA) might stay flat for a while, and growth could slow down a bit like a runner catching their breath. πββοΈπ¨
* The Silver Lining: Even with the spending, the business is tougher and more diverse than people think. Itβs not just one magic pill; itβs a whole platform.
My Take: The rocket isn't crashing, but it might be stopping for fuel. β½οΈ
Do you think $33 is a bargain or a ceiling? Let me know below! π
@TigerStars @Tiger_comments @Daily_Discussion @TigerEvents @TigerWire
$Hims & Hers Health Inc.(HIMS)$
Comments